Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07189377 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors

Study acronym: CLEAR-HBV
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2025 to Sep 24, 2025 · Eligibility criteria revised · Study description expanded, about 56 words · 1 morev2 Show 4 more changesShow less
    • Start date changed from estimate of Sep 2025 to Sep 24, 2025
    • Eligibility criteria revised
    • Study description expanded, about 56 words
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
Trial Details
NCT Number NCT07189377
Lead Sponsor University Health Network, Toronto
Conditions Hepatitis B Virus (HBV), Lung Transplant Recipient
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov